In April 2020, OSANG Healthcare Becomes the First Korean Company to win FDA Emergency Use Authorization

According to the report published in March, 2020 entitled “Mycoplasma genitalium Urethritis: Prevalence and Drug-Resistance Patterns” Mycoplasma gentitalium is one of the leading cause of male urethritis and according to a study conducted out of a total of 914 participants, 28.7% of population had Mycoplasma genitalium (MG) infection. As per the news of February, 2019 Mycoplasma had been isolated from rectum and anal canal in the patients suffering from Crohn’s disease, this, thus suggested that Mycoplasma is also responsible for prevailing gastrointestinal infections.      

Access Full Report at https://databridgemarketresearch.com/reports/global-mycoplasma-testing-in-clinical-market

Global mycoplasma testing in clinical market is expected to reach USD 423.60 million by 2027 from USD 249.31 million in 2019 growing with the CAGR of 7.0% in the forecast period of 2020 to 2027. The highly-sensitive PCR and qPCR had been designed, which has improved the specificity of testing to diagnose more than 90 species of mycoplasma. The test involves various products such as readers, assays, instruments and kits and reagents, which boost the market growth. A large number of market players are involved in manufacturing of devices and consumables used for the identification of various mycoplasma species which paves the way for market growth.           

The rising number of disease across the world will drive the market's growth rate

Various types of infectious disease are increasing nowadays due to unhygienic conditions and many other reasons. Mycoplasma is known to cause various kinds of disease by targeting different body parts. Mycoplasma is known to cause urethritis, Crohn’s disease, pneumonia, neurological disease, among others. As mycoplasma is the leading cause of various diseases, the need for clinical testing is increasing to achieve best treatment at correct interval of time. Thus, this signifies the rising number of diseases acting as drivers for the growth of global mycoplasma testing in the clinical market.

Report Scope and Market Segmentation

Segment Analysis:

Global mycoplasma testing in clinical market is categorized into four notable segments which are based on products, technique, disease area and end user.

• On the basis of products, the mycoplasma testing in clinical market is segmented into kits and reagents, instruments and services. In 2020, kits & reagents segment is expected to dominate the market with 53.81% market share because kits and reagents are repeatedly purchased as products for the detection of mycoplasma.
• On the basis of technique, the mycoplasma testing in clinical market is segmented into microbial culture techniques/direct assay, polymerase chain reaction, ELISA, DNA staining/ indirect assay, enzymatic methods. In 2020, microbial culture techniques/direct assay segment is expected to dominate the market with 35.92% market share because these techniques are cost effective and highly specific when a positive result is obtained.
• On the basis of disease area, the mycoplasma testing in clinical market is segmented into respiratory, urogenital, gastrointestinal, cardiovascular, musculoskeletal, and others. In 2020, the respiratory segment is expected to dominate the market with 35.87% because mycoplasma affects children & adults with mild to severe pneumonias.

The respiratory segment will dominate the disease area segment of the mycoplasma testing in clinical market

The respiratory segment will emerge as the dominating segment under disease area with approximately 36.00% market share. This is because of the growing number of infrastructural development activities in the market especially in the developing economies. Further, growth and expansion of the healthcare industry all around the globe will further bolster the growth of this segment.

• On the basis of end user, the mycoplasma testing in clinical market is segmented into hospitals and diagnostics laboratories. In 2020, diagnostics laboratories segment is expected to dominate the market with 54.64% market share because diagnostics laboratories are fully equipped with all the products required for the detection of mycoplasma and presence of skilled professional.

The diagnostics laboratories segment will dominate the end user segment of the mycoplasma testing in clinical market

The diagnostics laboratories centers segment will emerge as the dominating segment end user segment. This is because of the growing number of diagnostics laboratories in the market especially in the developing economies. Further, growth and expansion of research development services on a global scale will further bolster the growth of this segment.

Major Players         

Data Bridge Market Research recognizes the following companies as the market players in market: AB ANALITICA s.r.l. (Italy), bioMérieux SA (France), ELITechGroup (France), Liofilchem S.r.l. (Italy), Agilent Technologies, Inc. (U.S.), PromoCell GmbH (Germany), F. Hoffmann-La Roche Ltd (Switzerland), OSANG Healthcare (south Korea), Sacace Biotechnologies Srl (Italy), Lonza (Switzerland), Merck KGaA (Germany), Seegene Inc. (South Korea), Clongen Laboratories, LLC (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Charles River Laboratories (U.S.), Bionique Testing Laboratories, Inc. (U.S.) and ZEAKON Diagnostics (U.S.).

Market Development

• In April 2020, OSANG Healthcare becomes the first Korean company to win FDA emergency use authorization. This helps the company to develop with strategic planning and stability within the market.
• In April 2018, ELITechGroup and R-Biopharm announced a worldwide agreement to expand their Real-Time PCR assay portfolio. This helped the company work with other organizations and expand its expertise in the field of PCR.
• In August 2020, Liofilchem S.r.l launched AF Genital System, VTM, Lockable contact plates having improved configuration used for microbial testing. This technological advancement helped the company diversify its product portfolio, enhancing its revenue.
• In July 2020, bioMérieux SA launched BIOFIRE MYCOPLASMA test, indicated for mycoplasma detection in biopharmaceutical products. This product launch helped the company to enhance its product portfolio.

Regional Analysis

Geographically, the countries covered in the market report are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, UAE, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

As per Data Bridge Market Research analysis:

North America is the dominant region in mycoplasma testing in clinical market during the forecast period 2020 - 2027

North America region is expected to dominate in the global mycoplasma testing in clinical market due to increased research and development and kits & reagents segment is expected to grow with the highest growth rate in the forecast period of 2020 to 2027 because of repeated purchase of consumables for the detection of mycoplasma in cell culture.

Asia-Pacific is estimated to be the fastest-growing region in mycoplasma testing in clinical market the forecast period 2020 - 2027

As a result of cell culture contamination, Japan is driving the expansion of the Asia-Pacific mycoplasma testing in clinical markets, and the kits and reagents segment is dominant in the nation.  

COVID-19 Impact

The COVID-19 outbreak has had a detrimental impact on all sectors of the economy and is still having a negative effect. When compared to other industries, the biopharmaceutical industry and adjacent markets have not been considerably affected. A study released in May 2022 found a connection between the quantity of mycoplasma tests and COVID-19-related non-pharmaceutical interventions (NPIs). The incidence of M. pneumonia following the adoption of COVID-19 NPIs was examined in this study. This study revealed a decline in M. pneumoniae detection throughout the epidemic. Globally, this decrease was noticed between March 2020 and March 2021.

For more detailed information about the mycoplasma testing in clinical https://www.databridgemarketresearch.com/reports/global-mycoplasma-testing-in-clinical-market